donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
GSK GlaxoSmithKline
43.350
-0.350-0.80%
Pre Mkt Price
43.240
-0.11-0.25%
YOY
Do not show
Hide blank lines
(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31(Q3)2021/09/30
Investing cash flow
Cash flow from continuing investing activities
Net PPE purchase and sale
-31.71% -216M 11.14% -1.03B 9.56% -435M 4.83% -256M
Net intangibles purchase and sale
-311.43% -370M -507.85% -987M -63.76% 104M -153.52% -900M
Net business purchase and sale
17.65% -70M -93.85% 185M -3200% -33M -158.62% -34M
Net investment purchase and sale
-- 0 1900% 18M -- 0 -- 0
Cash from discontinued investing activities
Investing cash flow
-7385.42% -3.59B -182.23% -1.78B -594.23% -361M -111.25% -1.18B
Financing cash flow
Cash flow from continuing financing activities
Net issuance payments of debt
179220% 8.96B 50.21% -2B -174.61% -1.42B 92.01% -226M
Net common stock issuance
-20% 12M -27.59% 21M 0% 1M -50% 1M
Cash dividends paid
-0.63% -952M -0.55% -4B -0.53% -951M -0.53% -951M
Net other financing activities
623.33% 314M -77.87% 27M 251.92% 158M 87.27% -7M
Cash from discontinued financing activities
Financing cash flow
679.43% 7.97B 25.1% -7.59B -27.54% -2.77B 67.4% -1.39B
Net cash flow
Beginning cash position
-27.46% 3.82B 8.92% 5.26B -12.64% 3.19B -58.36% 3.2B
Current changes in cash
733.3% 6.92B -400.85% -1.41B -61.18% 632M 99.62% -15M
Effect of exchange rate changes
134.29% 12M 25.64% -29M 63.64% -8M 128.89% 13M
End cash Position
160.06% 10.75B -27.42% 3.82B -27.42% 3.82B -12.64% 3.19B
Free cash flow
8539.13% 1.94B -19.04% 5.02B 4.15% 3.14B 500% 1.28B
Investing cash flow
Cash flow from continuing investing activities
Net PPE purchase and sale
-31.71% -216M 11.14% -1.03B 9.56% -435M 4.83% -256M
Net intangibles purchase and sale
-311.43% -370M -507.85% -987M -63.76% 104M -153.52% -900M
Net business purchase and sale
17.65% -70M -93.85% 185M -3200% -33M -158.62% -34M
Net investment purchase and sale
-- 0 1900% 18M -- 0 -- 0
Cash from discontinued investing activities
Investing cash flow
-7385.42% -3.59B -182.23% -1.78B -594.23% -361M -111.25% -1.18B
Financing cash flow
Cash flow from continuing financing activities
Net issuance payments of debt
179220% 8.96B 50.21% -2B -174.61% -1.42B 92.01% -226M
Net common stock issuance
-20% 12M -27.59% 21M 0% 1M -50% 1M
Cash dividends paid
-0.63% -952M -0.55% -4B -0.53% -951M -0.53% -951M
Net other financing activities
623.33% 314M -77.87% 27M 251.92% 158M 87.27% -7M
Cash from discontinued financing activities
Financing cash flow
679.43% 7.97B 25.1% -7.59B -27.54% -2.77B 67.4% -1.39B
Net cash flow
Beginning cash position
-27.46% 3.82B 8.92% 5.26B -12.64% 3.19B -58.36% 3.2B
Current changes in cash
733.3% 6.92B -400.85% -1.41B -61.18% 632M 99.62% -15M
Effect of exchange rate changes
134.29% 12M 25.64% -29M 63.64% -8M 128.89% 13M
End cash Position
160.06% 10.75B -27.42% 3.82B -27.42% 3.82B -12.64% 3.19B
Free cash flow
8539.13% 1.94B -19.04% 5.02B 4.15% 3.14B 500% 1.28B
Currency Unit
GBPGBPGBPGBP
Accounting Standards
NonUS-GAAPNonUS-GAAPNonUS-GAAPNonUS-GAAP

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Merck KGaA; Lyell Immunopharma; CEPI; Innovax and Xiamen University; VBI; and Viome. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
CEO: Walmsley, Emma N.
Market: NYSE
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...